a b s t r a c t
Hypoxic-ischemic (HI) brain injury in newborns results in serious damage. Magnesium sulfate has been clinically used as a cyto-protective agent against HI brain injury in newborns in some countries, including Japan. However, it is not clear how magnesium exerts this effect and how it acts on the individual types of cells within the newborn brain. In this study, we exposed cultured rat oligodendrocyte precursor cells to magnesium sulfate during the period when they differentiate into oligodendrocytes, and showed that magnesium-exposed oligodendrocytes exhibited more resistance to HI injury. Our data may support the use of magnesium sulfate in the clinical setting.
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White matter injury after hypoxic-ischemic (HI) injury results in serious damage to the developing brain. Many affected infants suffer from severe neurological deficits and lifelong handicaps. Therefore, therapy to protect the white matter and reduce the injury is urgently needed. In seeking therapeutic agents that can provide protection to the vulnerable developing brain, magnesium sulfate has been examined for its potential. Although still controversial, magnesium is one of the supportive drugs used in newborn HI injury, often in conjunction with therapeutic hypothermia (Shea and Palanisamy, 2015) . However, effects of magnesium in newborn hypoxia and/or ischemia are not fully understood, and it is important to evaluate whether and how magnesium can protect developing brains against hypoxic stress. In this study, therefore, we examined the effects of magnesium sulfate on oligodendrocyte lineage cells (oligodendrocytes and oligodendrocyte precursor cells), which constitute the major cell types in cerebral white matter.
All experiments were performed following institutionally approved protocol by Massachusetts General Hospital Subcommittee on Research Animal Care, and in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Primary oligodendrocyte precursor cells (OPCs) were isolated * Corresponding author. Tel.: +1 617 724 9503. E-mail address: karai@partners.org (K. Arai).
from neonatal rat brain cortex as previously described (Arai and Lo, 2009). For proliferation, OPCs were cultured in Neurobasal media containing 1% penicillin/streptomycin, 2 mM l-glutamine, 10 ng/ml basic fibroblast growth factor, 10 ng/ml platelet-derived growth factor-AA, and 2% B27 supplement. For differentiation of OPCs into mature oligodendrocytes, culture media was switched to differentiation media (Dulbecco's Modified Eagle's Medium (DMEM) containing 1% penicillin/streptomycin, 10 ng/ml ciliary neurotrophic factor, 15 nM triiodo-l-thyronine, and 2% B27 supplement).
Maturation of OPCs was assessed on the seventh day after the start of differentiation. Western blots using anti-myelin basic protein (MBP) and glutathione-S-transferase (GST) pi, which are markers for mature oligodendrocytes, and PDGF receptor-␣ (PDGFR-␣), a marker for OPCs, were done to confirm the maturation state of the cells. Western blot of cell lysates was carried out using mouse monoclonal antibodies to MBP (1:500 dilution, Thermo scientific), rabbit polyclonal antibodies to GST-pi (1:1000 dilution, MBL international), rabbit polyclonal antibodies to PDGFR-␣ (1:1000 dilution, Santa Cruz) and mouse monoclonal antibodies to ␤-actin (1:10,000 dilution, Sigma Aldrich). OPC maturation was also assessed by quantitative real-time PCR (QRT-PCR) on the third day after switching the culture media. RNA was isolated with RNeasy Plus Mini kit (QIAGEN, Hilden, Germany), and first-strand cDNA was synthesized with PrimeScript RT reagent (Takara-Clonetech). QRT-PCR was performed using SYBR Premix http://dx.doi.org/10.1016/j.neures.2015.12.004 0168-0102/© 2015 Elsevier Ireland Ltd and the Japan Neuroscience Society. All rights reserved.
